| Project/Area Number |
10672153
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
応用薬理学・医療系薬学
|
|---|
| Research Institution | JICHI MEDICAL SCHOOL |
|---|
Principal Investigator |
SUGIMOTO Koichi JICHI MEDICAL SCHOOL, DEPT.OF CLIN.PHARMACOL., ASSISTANT PROFESSOR, 医学部, 講師 (90244491)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSURUOKA Shuichi JICHI MEDICAL SCHOOL, DEPT.OF CLIN.PHARMACOL., RESEARCH ASSOCIATE, 医学部, 助手 (50285798)
FUJIMURA Akio JICHI MEDICAL SCHOOL, DEPT.OF CLIN.PHARMACOL., PROFESSOR, 医学部, 教授 (90156901)
|
|---|
| Project Period (FY) |
1998 – 2000
|
| Project Status |
Completed (Fiscal Year 2000)
|
| Budget Amount *help |
¥3,000,000 (Direct Cost: ¥3,000,000)
Fiscal Year 2000: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 1999: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1998: ¥1,300,000 (Direct Cost: ¥1,300,000)
|
|---|
| Keywords | Caco-2 cell / P-glycoprotein / cytochrome P-450 3A4 / drug interaction / phenobarbital / rifampicin / digoxin / チトクロムP-450 3A4 / Caco2 / シクロスポリン / プロブコール |
|---|
| Research Abstract |
Using cultured Caco-2 cell monolayers, we tried to investigate the involvement of cytochrome P-450 (CYP) 3A4 and P-glycoprotein (P-gp) and to predict drug interaction of orally administered agents in vitro. Probucol, a lipid-lowering drug, caused P-gp-independent suppression of cyclosporine A (a substrate of CYP3A4 and P-gp) transport across Caco-2 cell monolayers. Pretreatment with various inducers failed to augment the P-gp-induced drug extrusion into the apical side of Caco-2 cell monolayers. Microsome fraction from Caco-2 cells even treated with CYP inducers did not demonstrate oxidization of nifedipine which is mediated by CYP3A4.
We thus performed ex vivo experiments using intact rats. Microsome fractions from the intestinal epithelium and liver showed oxidation of nifedipine (averaged production rate ; 35 and 160 pmol/min/mg protein, respectively). We constructed ex vivo intestinal perfusion system and examined the absorption and secretion of P-gp substrate drug. P-gp inhibitor (verapamil, ketoconazole) increased the transport of digoxin, a P-gp substrate, to the adventitial side, and decreased the secretion into the luminal perfusate, indicating that this system can be used to assess the involvement of P-gp in the drug absorption at the intestinal tract. Treatment with phenobarbital, a CYP inducer, increased CYP3A4 activity in the liver (+ 130 %), but not intestinal epithelium. Another inducer, rifampicin, elevated CYP3A4 activity in the intestinal epithelium (+ 32 %) without affecting the activity in the liver. Rifampicin also enhanced the P-gp activity in the intestine. These results from ex vivo study suggest that CYP inducers may cause tissue-specific induction of CYP or P-gp activity. The mechanism of tissue-specific induction of drug metabolism or drug extrusion needs to be clarified. It may be helpful to understand the mechanism of drug interaction.
|
